Caina Technology Co., Ltd. (301122.SZ) manufactures and sells disposable syringes, needles and related medical consumables principally for human healthcare, veterinary and laboratory applications. The company produces disposable sterile safe self-destructing syringes; disposable insulin syringes; disposable sterile insulin pen needles; disposable sterile blood collection needles; nutritional interface syringes; safety needles; copper-seat needles; aluminum-plastic injection needles; sheathed syringes; continuous syringes; reusable syringes; petri dishes; bacterial filter boxes; polypropylene hub disposable needles; hypodermic reusable needles; detectable needles; TPX syringes; and plastic injectors, among other sterile medical devices. Founded in 2004 and headquartered in Jiangyin, China, Caina Technology operates three primary business segments spanning medical equipment, animal equipment and laboratory consumables, with products supplied domestically and internationally through OEM and ODM services leveraging advanced intelligent manufacturing facilities including automated clean rooms and sterilization lines. In recent developments, the company listed on the Shenzhen Stock Exchange in January 2022 and continues to invest in R&D through centers such as the Jiangyin Safe Self-Destructing Syringe Engineering Technology Research Center and Wuxi Veterinary Piercing Device Engineering Technology Research Center, though it reports declining revenues and net profits including a 15.86% revenue drop to 246 million yuan and 85.64% net profit decline in the first three quarters of 2025.